These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31187785)

  • 21. Does the degree of hypothalamic-pituitary-ovarian recovery after oral contraceptive pills affect outcomes of IVF/ICSI cycles receiving GnRH-antagonist adjuvant therapy in women over 35 years of age?
    Schmitz C; Bocca S; Beydoun H; Stadtmauer L; Oehninger S
    J Assist Reprod Genet; 2012 Sep; 29(9):877-82. PubMed ID: 22729431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intrauterine administration of hCG immediately after oocyte retrieval and the outcome of ICSI: a randomized controlled trial.
    Navali N; Gassemzadeh A; Farzadi L; Abdollahi S; Nouri M; Hamdi K; Mallah F; Jalilvand F
    Hum Reprod; 2016 Nov; 31(11):2520-2526. PubMed ID: 27680029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adenomyosis has no adverse effects on IVF/ICSI outcomes in women with endometriosis treated with long-term pituitary down-regulation before IVF/ICSI.
    Mijatovic V; Florijn E; Halim N; Schats R; Hompes P
    Eur J Obstet Gynecol Reprod Biol; 2010 Jul; 151(1):62-5. PubMed ID: 20409633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve.
    Lin MH; Wu FS; Hwu YM; Lee RK; Li RS; Li SH
    Reprod Biol Endocrinol; 2019 Jan; 17(1):7. PubMed ID: 30609935
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
    Ren J; Sha A; Han D; Li P; Geng J; Ma C
    Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of IVF/ICSI Outcomes in Endometriosis Patients With Recurrent Implantation Failure: Influence on Cumulative Live Birth Rate.
    Zhong C; Gao L; Shu L; Hou Z; Cai L; Huang J; Liu J; Mao Y
    Front Endocrinol (Lausanne); 2021; 12():640288. PubMed ID: 34393990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection.
    Takeuchi S; Minoura H; Shibahara T; Tsuiki Y; Noritaka F; Toyoda N
    Fertil Steril; 2001 Sep; 76(3):532-7. PubMed ID: 11532477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles.
    Yu S; Long H; Chang HY; Liu Y; Gao H; Zhu J; Quan X; Lyu Q; Kuang Y; Ai A
    Hum Reprod; 2018 Feb; 33(2):229-237. PubMed ID: 29300975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative study on the pregnancy outcomes of in vitro fertilization-embryo transfer between long-acting gonadotropin-releasing hormone agonist combined with transvaginal ultrasound-guided cyst aspiration and long-acting gonadotropin-releasing hormone agonist alone.
    Guo YH; Lu N; Zhang Y; Su YC; Wang Y; Zhang YL; Sun YP
    Contemp Clin Trials; 2012 Nov; 33(6):1206-10. PubMed ID: 22820320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET.
    Tsakos E; Tolikas A; Daniilidis A; Asimakopoulos B
    Arch Gynecol Obstet; 2014 Dec; 290(6):1249-53. PubMed ID: 25001569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study.
    Buendgen NK; Schultze-Mosgau A; Cordes T; Diedrich K; Griesinger G
    Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist.
    Lu X; Hong Q; Sun L; Chen Q; Fu Y; Ai A; Lyu Q; Kuang Y
    Fertil Steril; 2016 Nov; 106(6):1356-1362. PubMed ID: 27490046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pregnancy rates in an IVF program. Use of the flare-up protocol after failure with long regimens of GnRH-a.
    Karacan M; Erkan H; Karabulut O; Sarikamiş B; Camlibel T; Benhabib M
    J Reprod Med; 2001 May; 46(5):485-9. PubMed ID: 11396377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High Serum FSH is Associated with Brown Oocyte Formation and a Lower Pregnacy Rate in Human IVF Parctice.
    Xu H; Deng K; Luo Q; Chen J; Zhang X; Wang X; Diao H; Zhang C
    Cell Physiol Biochem; 2016; 39(2):677-84. PubMed ID: 27442586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response.
    Xiao ZN; Peng JL; Yang J; Xu WM
    Curr Med Sci; 2019 Jun; 39(3):431-436. PubMed ID: 31209815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged pituitary downregulation with gonadotropin-releasing hormone agonist improves the live-birth rate: a retrospective cohort study comparing 3 different protocols.
    Ruan M; Fang L; Yang S; Chen Z; Wu Y; Qu X; Zhao J; Cheng J
    Ann Palliat Med; 2021 Sep; 10(9):9984-9992. PubMed ID: 34628922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles.
    Mochtar MH; Danhof NA; Ayeleke RO; Van der Veen F; van Wely M
    Cochrane Database Syst Rev; 2017 May; 5(5):CD005070. PubMed ID: 28537052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conventional in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI): which is preferred for advanced age patients with five or fewer oocytes retrieved?
    Liu H; Zhao H; Yu G; Li M; Ma S; Zhang H; Wu K
    Arch Gynecol Obstet; 2018 May; 297(5):1301-1306. PubMed ID: 29417282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.